Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVO NASDAQ:LGVN NASDAQ:MRKR NASDAQ:PLUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$4.44-2.4%$4.84$3.80▼$59.40$5.67M1.6824,153 shs126,478 shsLGVNLongeveron$0.70-1.0%$0.80$0.48▼$1.80$22.11M-0.35213,591 shs387,200 shsMRKRMarker Therapeutics$1.47+0.7%$1.43$0.81▼$4.07$24.34M1.4454,864 shs51,749 shsPLURPluri$2.09-2.8%$2.70$1.99▼$5.96$23.20M0.649,918 shs6,364 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics-2.42%-4.10%-9.57%+6.47%-91.91%LGVNLongeveron-0.97%-12.13%-8.96%-37.23%-45.92%MRKRMarker Therapeutics+0.68%+7.30%-6.37%+12.21%-3.92%PLURPluri-2.79%-0.48%-9.91%-38.94%-57.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$4.44-2.4%$4.84$3.80▼$59.40$5.67M1.6824,153 shs126,478 shsLGVNLongeveron$0.70-1.0%$0.80$0.48▼$1.80$22.11M-0.35213,591 shs387,200 shsMRKRMarker Therapeutics$1.47+0.7%$1.43$0.81▼$4.07$24.34M1.4454,864 shs51,749 shsPLURPluri$2.09-2.8%$2.70$1.99▼$5.96$23.20M0.649,918 shs6,364 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics-2.42%-4.10%-9.57%+6.47%-91.91%LGVNLongeveron-0.97%-12.13%-8.96%-37.23%-45.92%MRKRMarker Therapeutics+0.68%+7.30%-6.37%+12.21%-3.92%PLURPluri-2.79%-0.48%-9.91%-38.94%-57.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 2.33HoldN/AN/ALGVNLongeveron 2.25Hold$5.50682.36% UpsideMRKRMarker Therapeutics 2.25Hold$10.00580.27% UpsidePLURPluri 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest APVO, LGVN, MRKR, and PLUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026MRKRMarker Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/16/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/15/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)6/5/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/2/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/26/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/22/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/20/2026MRKRMarker Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/19/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026LGVNLongeveron Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo TherapeuticsN/AN/AN/AN/A$17.42 per shareN/ALGVNLongeveron$1.20M18.25N/AN/A$0.25 per share2.81MRKRMarker Therapeutics$3.55M6.90N/AN/A$1.01 per share1.46PLURPluri$1.34M16.83N/AN/A($0.11) per share-19.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$25.97M-$197.60N/AN/AN/AN/A-198.50%-117.06%8/10/2026 (Estimated)LGVNLongeveron-$22.70M-$1.13N/AN/AN/A-1,844.49%-202.41%-140.67%8/12/2026 (Estimated)MRKRMarker Therapeutics-$12.16M-$0.61N/AN/AN/A-343.03%-73.29%-59.70%8/13/2026 (Estimated)PLURPluri-$22.58M-$4.53N/AN/AN/A-2,162.08%N/A-106.59%N/ALatest APVO, LGVN, MRKR, and PLUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026MRKRMarker Therapeutics-$0.18-$0.16+$0.02-$0.16$0.78 million$0.75 million5/14/2026Q3 2026PLURPluri-$0.66-$0.55+$0.11-$0.55$0.66 million$0.17 million5/13/2026Q1 2026APVOAptevo Therapeutics-$6.41-$6.41N/A-$6.41N/AN/A5/13/2026Q1 2026LGVNLongeveron-$0.19-$0.19N/A-$0.19$0.33 million$0.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A3.363.36LGVNLongeveron0.053.883.88MRKRMarker TherapeuticsN/A4.794.79PLURPluriN/A0.330.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%LGVNLongeveron10.01%MRKRMarker Therapeutics22.39%PLURPluri16.59%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.08%LGVNLongeveron7.42%MRKRMarker Therapeutics5.70%PLURPluri43.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics501.25 million1.25 millionNot OptionableLGVNLongeveron2031.15 million28.84 millionNot OptionableMRKRMarker Therapeutics6016.67 million15.72 millionNot OptionablePLURPluri15010.79 million6.13 millionNo DataAPVO, LGVN, MRKR, and PLUR HeadlinesRecent News About These CompaniesLab-grown coffee and chocolate could save both industriesJune 26, 2026 | msn.comPluri Secures Insider Advance Subscription to Boost LiquidityJune 22, 2026 | tipranks.comPlurilock Announces Results of Annual General MeetingJune 16, 2026 | newsfilecorp.comNPluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products ListingJune 2, 2026 | globenewswire.comPluri in Good-Faith Talks on EIB Loan ResolutionJune 1, 2026 | tipranks.comPluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest InMay 31, 2026 | uk.finance.yahoo.comPluri Insider Ups Holding During YearMay 28, 2026 | finance.yahoo.comPluri Analyst Ratings and Price Targets | NASDAQ:PLUR | BenzingaMay 19, 2026 | benzinga.comNewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth PlansApril 30, 2026 | quiverquant.comQPluri Announces Financing Through Unregistered Equity Securities DealMarch 27, 2026 | tipranks.comPluri Inc.: Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementMarch 26, 2026 | finanznachrichten.dePluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementMarch 26, 2026 | finance.yahoo.comPluri Regains Nasdaq Compliance, Restoring Listing StabilityMarch 2, 2026 | tipranks.comPluri Biotech Secures China Patent for Immune Cell TechFebruary 18, 2026 | contractpharma.comCPluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. PatentFebruary 18, 2026 | markets.businessinsider.comPluri's cell therapy to extends lifespan and combat chronic diseaseFebruary 17, 2026 | i24news.tvIPluri showcases cell expansion platform as Resbiomed program advancesFebruary 10, 2026 | finance.yahoo.comPluri's Alejandro Weinstein on the future of cell-based technologyFebruary 2, 2026 | msn.comPluri Faces Nasdaq Noncompliance Notice, Evaluating Listing OptionsJanuary 22, 2026 | tipranks.comPluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich BiomaterialsJanuary 22, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPVO, LGVN, MRKR, and PLUR Company DescriptionsAptevo Therapeutics NASDAQ:APVO$4.44 -0.11 (-2.42%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$4.42 -0.02 (-0.45%) As of 06/30/2026 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Longeveron NASDAQ:LGVN$0.70 -0.01 (-0.97%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$0.72 +0.02 (+2.56%) As of 06/30/2026 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Marker Therapeutics NASDAQ:MRKR$1.47 +0.01 (+0.68%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$1.48 +0.02 (+1.02%) As of 06/30/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.Pluri NASDAQ:PLUR$2.09 -0.06 (-2.79%) Closing price 06/30/2026 03:58 PM EasternExtended Trading$2.09 0.00 (0.00%) As of 06/30/2026 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
